Recent Advances in the Treatment of Peritoneal Metastasis from Gastric Cancer

Yutaka Yonemura1*, Emel Canbay1, Haruaki Ishibashi1, Masamitu Hirano1, Akiyoshi2, Mizumoto1, Nobuyuki Takao1, Masumi Ichinose3, Kousuke Noguchi1, Yang Liu1, Satoshi Wakama1, Shinya Shimada2, Federico Coccolini3, Keizou Taniguchi4 and Sachio Fushida5

1Peritoneal Surface Malignancy Treatment Center, Kishiwada Tokushukai Hospital and Kusatsu General Hospital, Osaka, Shiga, Japan
2Department of General Surgery Department, Kumamoto General Hospital, Yatsumura, Japan
3Department of General Surgery, Ospedale Maggiore, Parma, Italy
4Department of Surgery, Teikyo University Hospital, Yokohama, Japan
5Department of Gastroenterological Surgery, Kanazawa University, Kanzawa, Japan

Abstract

Background: Peritoneal metastasis (PM) from gastric cancer (GC) was once considered a lethal disease. After the late 1990s, the therapeutic goal changed from palliative to curative intent because of a development of a comprehensive treatment combining cytoreductive surgery (CRS) and perioperative chemotherapy.

Methods: Recent advances in the treatment of PM from GC reported in 18 studies including 2327 patients were reviewed.

Results: In patients with PM, systemic chemotherapy alone had a limited and non-curative effect. In contrast, radical gastrectomy plus neoadjuvant intraperitoneal/systemic chemotherapy (NIPS), early postoperative intraperitoneal chemotherapy (EPIC), or postoperative S1 treatment was shown to improve the survival of patients with cytology-positive (Cy1) peritoneal lavage fluid without macroscopic PM (P0) (P0Cy1). After 5 years, 23 among 154 patients were disease free. For the treatment of patients with macroscopic PM (P1), exploratory laparotomy to determine the peritoneal cancer index (PCI) and neoadjuvant laparoscopic hyperthermic intraperitoneal perfusion (LHIPEC) were performed. The combination of NIPS and LHIPEC was effective in patients with P1, but NIPS or LHIPEC alone were ineffective and all patients receiving one or the other died. In contrast, the 5-year survival rate after cytoreductive surgery (CRS) + HIPEC ranged from 6% to 13%, and 18 among 284 patients were disease free at 5 years.

Conclusion: Although CRS and NIPS have an important role in treatment of PM from GC, complete cytoreduction by gastrectomy and peritonectomy after NIPS combined with intraoperative HIPEC, EPIC, and late postoperative chemotherapy may cure the patients with P0Cy1 or P1 disease.

Synopsis

Recent advances in the treatment of PM from GC were reviewed. Radical gastrectomy plus perioperative chemotherapy improved the survival of patients with intraperitoneal micrometastasis. Complete cytoreduction combined with perioperative chemotherapy may cure the patients with macroscopic PM. Most frequent cause of gastric cancer (GC) death is peritoneal metastasis (PM), with death occurring in 53%-60% of advanced gastric cancer patients. PM from GC is considered an independent prognostic factor for poor prognosis [1]. Accordingly, PM from GC has been considered a lethal condition. Despite the development of many new systemic chemotherapy, systemic chemotherapy of PM from GC remains poor [2-7]. Recently, intraperitoneal chemotherapy (IPC) was proposed as an effective treatment to improve survival [8]. Yonemura Y et al. [8] and Glehen O et al. [9] reported that IPC/hyperthermic intraperitoneal chemoperfusion (HIPEC) combined with Cytoreductive Surgery (CRS) (but not IPC alone) significantly improved the survival of GC patients with PM. Additionally, some patients were cured by a combination of neoadjuvant IPC, CRS, HIPEC, and postoperative chemotherapy [10]. The present review demonstrates that recent advances in the treatment of PM from GC have significantly improved prognosis.
Table 1: Outcome of patients with peritoneal metastasis from gastric cancer treated by systemic chemotherapy alone.

| Authors | treatments and tumor status | No. of Patients | MST | Response rate | 1 year survival rate | 5 year survival rate | 5 year disease free survivors | Side effects |
|---------|-----------------------------|-----------------|-----|---------------|---------------------|---------------------|-------------------------------|-------------|
|         |                             |                 |     |               |                     |                     |                               |             |
| Macroscopic peritoneal metastasis (P1 group) |                             |                 |     |               |                     |                     |                               |             |
| Nishina T [4] | 5-FU+(MTX) | 49 | 7.7m | Not described | 27.10% | 0% | 0 | 0-28.6% (0%) |
| Koizumi W [2] | S1+CDDP | 148 (51)# | 13.0m | 54% | 54.10% | NR | 0 | 0-11% (0%) |
| Kodera Y [15] | Gastrectomy + S-1 | 48 | 23.5m | Not described | 78% | 32% | 1 | 2-13% (0%) |
| Wilke H [7] | Ramucirumab | 330 (163)# | 9.6m | 17% | 42% | NR | NR | 81% (12%) |
| Ramucirumab+paclitaxel | 335 (152)# | 7.4m | 28% | 30% | NR | NR | 63% (16%) |

Cytology-positive peritoneal lavage fluid and without macroscopic peritoneal metastasis (P0Cy1 group)

| Authors | treatments and tumor status | No. of Patients | MST | Response rate | 1 year survival rate | 5 year survival rate | 5 year disease free survivors | Side effects |
|---------|-----------------------------|-----------------|-----|---------------|---------------------|---------------------|-------------------------------|-------------|
| Hong SH [6] | Various regimen $ | 211 | | | | | | |
| Measurable disease | 74 | 11.6m | Not described | 49.80% | NR | 0 | - |
| Non-measurable disease | 137 | 18.0m | Not described | 68.40% | 12% | 0 | - |
| Gastrectomy+chemotherapy | 44 | 29.3m | Not described | 85.40% | 7.70% | 0 | - |
| gastrectomy alone | 61 | 12.5m | not described | 54.30% | 3.40% | 0 | - |
| Wilke H [7] | Ramucirumab | 330 (163)# | 9.6m | 17% | 42% | NR | NR | 81% (12%) |
| Ramucirumab+paclitaxel | 335 (152)# | 7.4m | 28% | 30% | NR | NR | 63% (16%) |

Limits of systemic chemotherapy for peritoneal metastasis from gastric cancer

Table 1 shows the effect of systemic chemotherapy on survival in GC patients with macroscopic PM (P1 group). In patients in P1 group treated with systemic chemotherapy alone, median survival time (MST) ranged from 5.0 to 13.0 months, and the one- to 5-year survival rates after systemic chemotherapy alone were reported to be 7.7%-13.0% and 0%-3.4%, respectively. [2,4-7] Hong SH reported that overall survival (OS) was associated with the extent of PM [6]. Although a small number of patients survived longer than 5 years after systemic chemotherapy and gastrectomy, all patients died of PC within 8 years after chemotherapy. Accordingly, the effect of systemic chemotherapy on survival improvement is limited, and systemic chemotherapy alone cannot cure patients with PM. The reasons include the existence of the plasma-peritoneal barrier [11] and cancer stem cells [12].

Treatment for intraperitoneal micrometastasis (cytology-positive (Cy1) peritoneal lavage fluid without macroscopic PM (P0); P0Cy1 group) by systemic chemotherapy or IPC

The 5-year survival rate after radical gastrectomy in P0Cy1 patients is reported to be only 2% [13]. Therefore, P0Cy1 patients are considered to have peritoneal metastases, and P0Cy1 gastric cancer is classified as stage IV [14]. As shown in Table 1, survival is significantly better in patients after radical gastrectomy plus postoperative oral S1 treatment than after gastrectomy alone [13,15,16]. Furthermore, disease-free survival longer than 5 years has been reported after gastrectomy [15,16]. Table 2 shows the outcomes of P0Cy1 patients treated with gastrectomy plus IPC. Fujiwara Y [17] and Yonemura Y [18] treated PoCy1 patients with radical gastrectomy after neoadjuvant intraperitoneal/systemic chemotherapy (NIPS) using oral S-1 + IP docetaxel with or without IP CDDP. After NIPS, positive cytology became negative cytology in 75%-78% of patients [17,18]. The 5-year survival rate after NIPS + gastrectomy was 42% and 2 patients remained in disease-free 5 years after NIPS [10]. In their P0Cy1 patients, a 3 arm randomized study, Kuramoto et al. [19] found that patients treated with extensive intraoperative peritoneal lavage (EIPL) + gastrectomy + early postoperative intraperitoneal chemotherapy (EPIC) (2-hour IP administration of CDDP at the time of abdominal closure) survived significantly longer than those treated with gastrectomy + EPIC or gastrectomy alone. In EIPL, the peritoneal cavity is extensively shaken and washed after intraperitoneal injection of 1L of saline, and the saline is completely aspirated. This procedure is done 10 times [19]. EIPL removes both peritoneal free cancer cells and those adhering to the peritoneal surface. EIPL + EPIC significantly improve the 5-year survival rate in P0Cy1 patients, because it significantly decreases the number of cancer cells in the peritoneal cavity [19]. Imano et al. also reported that gastrectomy +EPIC using paclitaxel (PTX) changed positive cytology to negative cytology in 100% (10/10) of P0Cy1 patients, and that 5-year survival rate was 25% [20]. These results strongly indicate that postoperative oral S1, NIPS, or EPIC can eradicate intraperitoneal micro-metastasis in 25%-44% of P0Cy1 patients, bringing about cure [17,18,20,21].

Intraperitoneal chemotherapy (IPC) for peritoneal metastasis (P1 group)

Recently, IPC has shown encouraging results for the treatment of PM, and has the following advantages:

1) The drugs act directly on not only cancer cells floating in the peritoneal fluid but also metastatic nodules on the peritoneal surface.

Remedy Publications LLC.
2) IPC achieves a significantly higher drug concentration in the peritoneal cavity as compared with systemic chemotherapy.

3) The half-life of high molecular weight drugs in the peritoneal cavity is prolonged and systemic toxicity is reduced.

However, IPC does not work in patients with peritoneal adhesions. Accordingly, IPC is mainly used preoperatively. Additionally, drug penetration distance from the peritoneal surface is just several hundred µm for methotrexate, 5FU, paclitaxel, and drug to drug. The depth of penetration from the peritoneal surface extends the treatable area of subperitoneal tissue. Systemic chemotherapy can be effective against deep seated tumors that are inaccessible through subperitoneal arterial capillaries but inaccessible through IPC. This strategy is known as neoadjuvant intraperitoneal/systemic chemotherapy (NIPS). Taxans are high molecular weight compounds. IP administered taxans are gradually absorbed through lymphatic stomata or omental milky spots, and migrate into lymph nodes and thoracic ducts. In contrast, low molecular weight compounds like mitomycin C (MMC) or CDDP are rapidly absorbed from peritoneal surface into subperitoneal blood vessels. The area under the curve ratios of the intra-abdominal space to the plasma after IP administration of the drugs are about 1000 for paclitaxel (PTX), 207-552 for docetaxel (DTX), 10-24 for MMC, and 12-21 for CDDP [27-30]. To achieve high loco-regional dose intensity in the peritoneal cavity and to reduce systemic toxicities, taxans (PTX and DTX) are the ideal drugs for IPC [31,32]. From the phase I studies, the maximum tolerated dose (MTD) and recommended dose (RD) were 90 mg/m² and 80 mg/m² for PTX, 27 and 50 mg/m² and 45 g/m² for DTX [28]. Table 3 shows the clinical outcomes of NIPS using IP administration of taxans for PM from gastric cancer.

The incidence of Grade 3, 4, or 5 side effects after IPC was lower after IPC with taxans (6.3% to 18.5%), [18,32-34] and the incidences are lower than those after systemic chemotherapy (0% to 81%) (Table 1,3) [2,4,5,6,7]. Histologic and cytologic responses to NIPS were excellent (Table 3). Histologic responses of grade 2 and 3 (viable cancer cells remaining in less than one third of the tumorous area [14]) disappeared completely in 25% of patients treated with NIPS using 5FU + PTX [21]. Macroscopic PM disappeared completely 15 (50%) of 30 patients after NIPS using DTX + CDDP [32,34], and in 52% of patients after NIPS using S1 + DTX (Table 2) [33]. In contrast, response rates were lower after systemic chemotherapy than after IPC (Table 1) [2,5,7].

Negative peritoneal wash cytology at the time of CRS was reported to be a significant favorable prognostic factor [34]. IP port cytology showed a change from positive cytology to negative cytology after IPC in 63%-67% of patients (Table 3) [32,34]. Histologic and cytologic effects of NIPS were independent prognostic factors after CRS [21,34]. Accordingly, NIPS is a powerful modality of intraperitoneal micrometastasis and macroscopic PM eradication, and thereby PM down-staging.

The role of cytoreductive surgery in the management of primary tumors, regional lymph node metastasis, and peritoneal metastasis

Survival was significantly worse NIPS alone than after NIPS + radical gastrectomy [21,32]. Ishigami et al. reported that 1-year and 5-year survival rates were 56% and 0% after NIPS alone, and 73% and 16% after NIPS + gastrectomy [21]. Furthermore, the 5-year survival rate in patients who received CCR-0 resection after NIPS was 25%, and 4 patients had no recurrence 5 years after gastrectomy [21]. Accordingly, gastrectomy plus D2 dissection improves long-term survival if macroscopic PMs completely disappear after NIPS. The rate of postoperative Grade 3 or 4 morbidities of IPC + gastrectomy was 0%-25%, but the rate of postoperative mortality was 0% [21,33]. Accordingly, gastrectomy + D2 dissection after NIPS can be performed safely with acceptable morbidities. In contrast, 5-year survival rates

| Authors         | Treatments | Patients | MST | Response | Grade 3, 4, 5 side effects | Postoperative |
|-----------------|------------|----------|-----|----------|---------------------------|--------------|
| Fujiwara Y      | NIPS (S1: Day 1-14) | 18 | 24,6m | Positive cytology | Grade 3,4,5 | 0-6% |
|                 | IP DOC Day 1 x 2 cycles | 14/18 (78%) |  | became negative | | |
| Yonemura Y      | NIPS (S: 1-8; Day 1-14) | 20 | 36m | Positive cytology | Grade 5 | 0% |
|                 | IP DOC Day 1 and Day 8 x 3 | |  | became negative | | |
| Kuramoto M      | EIPL + IP CDDP + gastrectomy | 30 | 36m | 85% | 43.80% | 8 |
|                 | IP CDDP + gastrectomy | 29 | 16m | 62% | 4.50% | 1 |
|                 | gastrectomy alone | 29 | 15m | 58% | 0% | 0 |
| Imano M         | Gastrectomy + IP PTX | 10 | 38m | 100% | 25% | 2 |
|                 | Gastrectomy | 6 | 13m | 63% | 0% | 0 |

# EIPL: Extensive intraperitoneal peritoneal lavage

Table 2: Outcome of patients showing cytology-positive peritoneal lavage fluid and no macroscopic peritoneal metastasis (POCy1 group) who were treated with IP chemotherapy.
after NIPS combined with incomplete cytoreduction (CCR-1) by radical gastrectomy without resection of PM were only low of 0%-2% [21,32,34] and all patients died of the disease (Table 3). Distant PM can be completely removed by peritonectomy procedures [35] but not by ordinary surgical techniques [21]. Table 4 shows the outcomes of patients with PM treated with radical gastrectomy + peritonectomy + HIPEC with or without NIPS. Five-year survival rates ranged from 6% to 13% [9,34,31,34]. Additionally, 18 of 284 patients were disease free 5 years after this treatment [9,29,36,37]. CCR-0 resection is the most powerful prognostic factor, and the 5-year survival rate after CCR-0 resection using peritonectomy ranged from 6% to 15% [36,37,38]. Accordingly, after radical gastrectomy and resection of PM by peritonectomy techniques, CCR-0 resection can be performed for wide spread PM to increase long-term survival rates and even bringing about cure. However, the postoperative morbidities and mortalities were higher after peritonectomy + HIPEC than after gastrectomy + NIPS (Table 3,4) [35,39]. Because of the high morbidity and mortality rates (0% - 6.5%, mean: 4.3%), strict patients selection is vital [9].

Cut-off pueritoneal cancer index (PCI) values [30]

As mentioned above, CCR-0 has been credited with increasing life expectancy. However, postoperative mortality after gastrectomy + peritonectomy is still high [34,36,37]. The smaller the area of sector and organ resection, the lower is postoperative morbidity and mortality. Cut-off PCI values suggesting favorable long-term survival after CRS have been reported [35,36,40]. Yonemura Y et al. proposed cut-off of ≤6, corresponding to a low postoperative morbidity (2.0%) and a favorable 5-year survival rate (18%) [10]. Coccolini F et al. performed a systematic review with meta-analysis of 1072 GC patients with PM [43]. CCR-0 vs. CCR-1 achieved favorable 1-year and 5-year survival rate (Risk Ratio: 2.41 and 7.96), respectively. They concluded that PCI cut-off value for favorable survival after CCR-0 resection was ≤12. Yonemura Y et al. studied the risk factors for PM recurrence after CCR-0 from 193 GC patients [10]. Median overall survival was 21.6 months, and 5-year survival rate was 18%. Five years after CRS, 11 patients were disease free. Multivariate analysis identified small bowel peritoneal cancer index (SB-PCI) of ≤2 as an independent favorable prognostic factor. Patients with PCI ≤12 and SB-PCI ≤2 were the best candidate for CRS [10,41].

Effects and side effects of hyperthermic intraperitoneal chemoperfusion (HIPEC)

Hyperthermia acts synergistic with some kinds of anti-cancer drugs [31]. Additionally, hyperthermia enhances subperitoneal tissue penetration by drugs. HIPEC increased the depth of CDDP and carboplatin penetration up to 3 mm from the peritoneal surface, [22] and 40 min. of HIPEC increased the depth of DTX penetration 1.46 mm [36,30,42]. Accordingly, HIPEC is considered to be an effective for PM treatment. In 2017, Yonemura Y et al. first reported the direct effect of HIPEC on PM from gastric cancer in 50 patients who underwent one cycle of neoadjuvant laparoscopic HIPEC and a 2nd exploratory laparoscopy one month later to evaluate the effect of HIPEC. [38] Ascites completely disappeared or decreased in volume in 22 of 34 (64.7%) patients and positive peritoneal cytology changed to negative cytology in 14 of 20 (70%) patients at the 2nd laparoscopy. The response was complete in 6 (12%) patients, and peritoneal cancer indices were significantly reduced from 14.2±10.7 at the 1st LHPEC to 11.8±11.0 at the 2nd laparoscopy (p=0.05) [38]. Furthermore, lesion size scores [43] in the sector of the small bowel mesentery at the 1st and 2nd laparoscopy were 6.56±2.92 and 5.25±3.78 (P=0.016). There was no intraoperative or postoperative complication and no mortality after LHPEC [38]. Accordingly, diagnostic and therapeutic laparoscopy can be performed safely in patients with PM from GC. LHPEC can be used as neoadjuvant treatment to reduce the tumor burden and achieve adequate control the disease. However, after one cycle of LHPEC, the mean PCI reduction was only 2.4. Accordingly, only one cycle of LHPEC is insufficiently to reduce the PCI score below the cut-off level. Furthermore, in a study of NLHPEC combined with 3 cycles of NIPS in 52 patients, NLHPEC was followed by a series of 3 x 3-week cycles of NIPS and then by laparotomy for cytoreductive
surgery and assessment of change in PCI [38]. Cytology was positive in 31 (59.6%) patients at the NLHIPEC, and changed from positive to negative in 22 (71%) of the 31 patients at laparotomy [38]. PCI ≤12 in 16 (30.2%) of 52 patients at NLHIPEC, and 31 (58%) of 52 patients after NLHIPEC+3 courses of NIPS (P=0.029). Additionally, PM disappeared in 6 (11.5%) patients. PCI at laparotomy decreased in 29 (55.8%) patients and increased 6 (11.6%) patients [38]. PCI was significantly lower at laparotomy (9.9±11.3) than that at NLHIPEC (14.8±11.4). After NLHIPEC+NIPS, complete cytoreduction was achieved in 30 (57.6%) patients [38]. Accordingly, NLHIPEC combined with 3 cycles of NIPS can effectively reduce PCI levels before CRS. This strategy impacts not only pretreatment PCI, but the enhancement of the effect of NLHIPEC by NIPS. During NLHIPEC and NIPS, additionally, patients can be selected for CRS by evaluating IP port cytology, serum tumor marker levels, and diagnostic imaging studies. In a randomized control trial of CRS+intraoperative HIPEC without neoadjuvant chemotherapy vs. CRS alone, Yang XJ et al. concluded that intraoperative HIPEC confers a significant survival benefit [40]. At the present time, comprehensive treatment combined with neoadjuvant chemotherapy, cytoreductive surgery and intraoperative HIPEC can be performed with intent to cure PM from GC.

Conclusion

Among the nine comprehensive treatment options (Figure 1), CRS after NIPS play important roles in achieving successful outcomes in GC patients with PM. NIPS reduces PCI and SB-PCI, thereby increasing CCR-0. Candidates for CRS should be selected during NIPS by cytological examination, serum tumor marker levels, and diagnostic imaging studies. After NIPS, radical gastrectomy+peritonectomy are recommended. The final goal is CCR-0 resection and the residual micrometastasis is treated with intraoperative HIPEC, EPIC, and late postoperative chemotherapy.

References

1. Chau I, Norman AR, Cunningham D, Waters J, Oates J, Ross P. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer- pooled analysis from three multicenter, randomized controlled trials using individual patient data. J Clin Oncol.

Table 4: Outcomes of cytoreductive surgery (radical gastrectomy+peritonectomy) and hyperthermic intraperitoneal chemoperfusion (HIPEC) with or without NIPS for removal of peritoneal metastasis from gastric cancer.

| Authors | No of patients | Drugs used in HIPEC | MST | 1 year | 5 year | No. of disease free | Prognostic factors | Mortality (Grade 5) |
|---------|----------------|---------------------|-----|--------|--------|-------------------|-------------------|-------------------|
| Glehen O | 49             | CRS+HIPEC (MMC+CDDP) | 9.2m | 43%    | 13%    | 5                 | CCR-0             | Grade 5: 6.5%     |
| [31]    |                | or LOHP+Irinotecan  | 21.3 | CCR-0  | 61%    | 4                 | PCI≤12            | Grade 3,4: 27.8%  |
| non-RCT |                | CCR-1:N=24         | 1.6  | 0%     |        |                   |                   |                   |
| Hall JJ [34] | 34          | CRS+HIPEC with MMC | 8.0  | 41%    | 6%     | 1                 | CCR-0             | Grade 5: 0%, Grade 3,4: 35% |
| non-RCT |                | no HIPEC           | 7.8  | 38%    | 17%    | 4                 |                   | Grade 5: 17.5%, Grade 3,4: 15% |
| Yang XJ [40] | 34          | CRS+HIPEC (CDDP+MMC) | 11.0 | 41.20% | NR     | NR                | HIPEC, CCR-0      | Grade 34.5: 11.7% |
| RCT     | 34             | CRS alone          | 6.5  | 29.40% | 0%     | 0                 | Systemic chemo. =>6 cycles | Grade 3,4,5: 14.7% |
| Yonemura Y [10] | 201          | NIPS+CRS+HIPEC    | 15.5m (CCR-0) | 65.00% | 15% | 12 | CCR-0, NIPS | Grade 5: 2% |
| non RCT | (DTX+CDDP)     | 8.0m (CCR-1)      | 38%  | 2%     | 0      | PCI≤6             |                   | Grade 3 or 4: 32% |

Figure 1: Treatment options for peritoneal metastases from gastric cancer.
Yutaka Yonemura, et al., Journal of Cancer and Cure

2018;22:2395-403.

2. Koizumi W, Narahara H, Haro T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215-21.

3. Bang YJ, Van Cutsem E, Feyreriova A, Chung HC, Shen L, Sawai K, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):887-97.

4. Nishina T, Boku N, Gotoh M, et al. Gastric Intestinal Oncology Study Group of the Japan Clinical Oncology Group. Randomized phase II study of second line chemotherapy with the best available 5-flourouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-flourouracil-containing regimens (ICCG407). Gastric Cancer. 2016;19:902-10.

5. Imamoto H, Oka K, Sakamoto J, Ishi H, Narahara H, Yumiba T, et al. Assessing benefit response in the treatment of gastric malignant ascites with non-measurable lesions: multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer. Gastric Cancer. 2011;14:81-90.

6. Hong SH, Shin YR, Roh SY, Jeon EK, Song KY, Park CH, et al. Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: retrospective analysis from a single center. Gastric Cancer. 2013;16(3):290-300.

7. Wilke H, Muro K, Van Custem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric cancer or gastro-esophageal junction adenocarcinoma (RAINBOW): a double-blind, randomized phase 3 trial. Lancet Oncol. 2014;15:1224-35.

8. Yonemura Y, Bando E, Sawa T, Yoshimitu Y, Endou Y, Sasaki T, et al. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol. 2006;32(6):661-5.

9. Gleen O, Schreiber V, Cotte E, Sayag-Beaujard AC, Osinsky D, Freyer G, et al. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from gastric cancer. Arch Surg. 2004;139(1):20-6.

10. Yonemura Y, Canbay E, Sako S, Ishibashi H, Hirano M, Mizumoto A, et al. Risk factors for recurrence after complete cytoreductive surgery and perioperative chemotherapy in peritoneal metastases from gastric cancer. J Integrx Oncol. 2016.

11. Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res. 1996;82:53-63.

12. Li F, Tiebe B, Massague J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res. 2007;17(1):3-14.

13. Bando E, Yonemura Y, Takeshita Y, Taniguchi K, Yasaki T, Yoshimitus Y, et al. Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg. 1999;178(3):256-62.

14. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma - 2nd English Edition - Gastric Cancer. 1998;1(1):10-24.

15. Kodera Y, Ito S, Mochizuki Y, Kondo K, Kosihaka K, Suzuki N, et al. A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity. Eur J Surg Oncol. 2009;35:1158-63.

16. Yonemura Y, Endou Y, Bando E. The usefulness of oral TS-1 treatment for potentially curable gastric cancer patients with intraperitoneal free cancer cells. Cancer Therapy. 2006;4:135-42.

17. Fujisawa Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, et al. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol. 2012;105(1):38-42.

18. Yonemura Y, Canbay E, Sako S, Haruaki Ishibashi, Masamitsu Hirano, Akiyoshi Mizumoto, et al. Phase II study of comprehensive treatment using perioperative chemotherapy combined with cytoreductive surgery for curatively resected gastric cancer patients with positive peritoneal wash cytology. Global J Gastroenterol Hepatol. 2014;2:1-6.

19. Kuramoto M, Shimada S, Ikeshima S, Matsu Y, Yagi Y, Matsuda M, et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg. 2009;250(2):242-6.

20. Imano M, Imamoto H, Itoh T, Sato T, Peng YF, Yasuda A, et al. Impact of intraperitoneal chemotherapy after gastrectomy with positive cytological findings in peritoneal washings. Eur Surg Res. 2011;47:254-9.

21. Ishigami H, Yamaguchi H, Yamashita H, Asakage M, Kitayama J. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer. 2017;20(Suppl 1):128-134.

22. Los G, Mutsaers PHA, van der Vijgh WJL, Beldew G, de Graaf PW, McVie JG, et al. "Direct diffusion of cis-diaminedichloroplatinum (II) in intraoperative rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy. Cancer Res. 1989;49,12:3830-84.

23. Sugarbaker PH, Van der Speeten. Surgical technology and pharmacology of hyperthermic perioperative chemotherapy. J Gastroenterol Oncol. 2016;7:29-44.

24. Kamei T, Kitayama J, Yamaguchi H, Soma D, Emoto S, Konno T, et al. Spatial distribution of intraperitoneally administered paclitaxel nanoparticles solubilized with poly (2-methacycloxyethyl phosphorylcoline co-n-butyl metacylate) in peritoneal metastatic nodules. Cancer Sci. 2011;102:200-5.

25. Yamaguchi H, Kitayama J, Ishigami H, Kazama S, Nozawa H, Kawai K, et al. Breakthrough therapy for peritoneal carcinomatosis of gastric cancer: Intraperitoneal chemotherapy with taxans. World J Gastroenterol. 2015;21:285-91.

26. Wang ZB, Li M, Li J. Recent advances in the research of lymphatic stomata. Anat Res (Hoboken). 2010;293(5):754-61.

27. Kurita N, Shimada M, Iwata T, Nishikawa M, Morimoto S, Yoshihaka K, et al. Intraperitoneal infusion of paclitaxel with S-1 for peritoneal metastasis of advanced gastric cancer: phase 1 study. J med invest. 2011;58:134-39.

28. Fujisada S, Kinoshita J, Kaji M, Hirono Y, Goda F, Yagi Y, et al. Phase II/II study of intraperitoneal docetaxel plus S-1 for gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2013;71:1265-72.

29. Miyamoto K, Shimada T, Sawamoto K, Sai Y, Yonemura Y. Disposition kinetics of taxanes in peritoneal dissemination. Gastroenterol Res Pract. 2012;2012:963403.

30. Yonemura Y, Endou Y, Bando E., Kuno K, Kawamura T, Kimura M, et al. Effect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancer. Cancer Let. 2004;22:2395-403.

31. de Bree E, Tsiftsis DD, "Experimental and pharmacologic studies in intraperitoneal chemotherapy from laboratory bench to bedside. Advances in peritoneal surface oncology. Springer. 2007;53-73.

32. Yonemura Y, Endou Y, Bando E, , Kuno K, Kawamura T, Kimura M, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery. J Surg Oncol. 2009;100(4):311-6.

33. Fushida S, Kinoshita J, Kaji M, Hirono Y, Goda F, Yagi Y, et al. Phase I/II study of intraperitoneal; docetaxel plus S-1 for gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2013;71:1265-72.

34. Yonemura Y, Imamoto H, Itoh T, Sato T, Peng YF, Yasuda A, et al. Impact of intraperitoneal chemotherapy after gastrectomy with positive cytological findings in peritoneal washings. Eur Surg Res. 2011;47:254-9.

35. Imamoto H, Canbay E, Sako S, Haruaki Ishibashi, Masamitsu Hirano, Yutaka Yonemura, et al. Phase II study of comprehensive treatment using perioperative chemotherapy combined with cytoreductive surgery for curatively resected gastric cancer patients with positive peritoneal wash cytology. Global J Gastroenterol Hepatol. 2014;2:1-6.
35. Yonemura Y, Elnemr A, Endou Y, Ishibashi H, Mizumoto A, Miura M, et al. Surgical Results of Patients with Peritoneal Carcinomatosis Treated with Cytoreductive Surgery Using a New Technique Named Aqua Dissection. Gastroenterol Res Pract. 2012;2012:521487.

36. Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemothermia. Ann Surg Oncol. 2010;9:2370-7.

37. Hall JJ, Loggie BW, Shen P, Beamer S, Douglas Case L, McQuellon R, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastroenterol Surg. 2004;8:454-63.

38. Yonemura Y, Ishibashi H, Hirano M, Mizumoto A, Takeshita K, Noguchi K, et al. Effects of Neoadjuvant laparoscopic Intrapertitoneal chemotherapy and neoadjuvant intraperitoneal/systemic chemotherapy on peritoneal metastasis from gastric cancer. Ann Surg Oncol. 2017;24(2):478-85.

39. Imano M, Imamoto H, Itoh T, Satou T, Peng YF, Yasuda A, et al. Safety of intraperitoneal administration of paclitaxel after gastrectomy with en-bloc D2 lymph node dissection. J Surg Oncol. 2012;105(1):43-7.

40. Yang XI, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: Final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575-81.

41. Coccolini F, Catena F, Glehen O, Yonemura Y, Sugarbaker PH, Piso P, et al. Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(7):911-9.

42. Yonemura Y, Canbay E, Sako S, Ishibashi H, Hirano M, Mizumoto A, et al. Pharmacokinetics of docetaxel during hyperthermic intraperitoneal chemotherapy for peritoneal metastasis. Gan To Kagaku Ryoho. 2014;41(12):2496-9.

43. Portilla AG, Shigeki K, Dario B, Marcello D. The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol. 2008;98(4):228-31.